ArticleMovement disorders clinical practice2026
Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReduced cardiac uptake on
objectivesThis study investigated factors limiting the clinical applicability of MIBG scintigraphy in everyday clinical practice.
methodsPatient records (2021-2022) were retrospectively reviewed, independent of whether MIBG scintigraphy was performed, for comorbidities and concomitant medication confounding its interpretation.
resultsSix hundred ninety five patients (640 Parkinson's disease, 22 multiple system atrophy, 33 progressive supranuclear palsy) were included. Factors potentially influencing cardiac MIBG binding were present in 55.3% with 18.1% exhibiting multiple factors. Medications with known drug-tracer interactions were found in 46.9% and comorbidities associated with reduced cardiac MIBG uptake in 20.9%.
conclusionsThe clinical utility of MIBG scintigraphy is frequently restricted by medications and comorbidities highlighting the need of careful planning in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.